Dr. Ellis on Genome Forward Breast Cancer Treatment

Matthew J. Ellis, MD, PhD
Published: Monday, Sep 26, 2011

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, explains that sometimes years after a patient is actually diagnosed with cancer they are screened and tested using a variety of genomic testing methods.

While this method is good Ellis believes it will soon change in favor of a method he calls genome forward medicine. This method of treatment creates a patients genomic map at diagnosis and uses that map to create a tailored treatment plan.

The only item holding this method back currently is the complexity of the breast cancer genome. The average breast cancer genome has 1-2 thousand mutations and out of these multiple mutations only a few will be the driver mutations. This means you will need to find the key driver mutations before you can accurately predict response rates and map out treatment using the genome forward method.

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, explains that sometimes years after a patient is actually diagnosed with cancer they are screened and tested using a variety of genomic testing methods.

While this method is good Ellis believes it will soon change in favor of a method he calls genome forward medicine. This method of treatment creates a patients genomic map at diagnosis and uses that map to create a tailored treatment plan.

The only item holding this method back currently is the complexity of the breast cancer genome. The average breast cancer genome has 1-2 thousand mutations and out of these multiple mutations only a few will be the driver mutations. This means you will need to find the key driver mutations before you can accurately predict response rates and map out treatment using the genome forward method.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x